Pancreatic Cancer Research

Clinical trialPhase 1Completed

Study of SRF617 in Patients With Advanced Solid Tumors

A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
16 March 2020
Ended
25 August 2023
Enrollment
85 participants
Sites
10
Primary outcomes
Dose Limiting Toxicity of SRF617
Sponsor type
Industry
Results posted
No
Last update
4 June 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

Detailed description public domain (ClinicalTrials.gov)

A Phase 1, open-label, first-in-human, study of SRF617, consisting of a monotherapy dose escalation, a monotherapy tumor biopsy expansion, combination dose escalations, and combination safety and efficacy expansions that will enroll patients with advanced solid tumors. The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SRF617 as monotherapy in patients with advanced solid tumors. The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy. The combination therapy dose escalation portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel, or SRF617 in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors. Once the SRF617 combination recommended Phase 2 doses are established, additional patients with select solid tumors may be enrolled in the respective combination expansion arm of the study. An additional quadruplet combination will also be explored in patients with advanced first line (1L) PDAC (i.e., SRF617 + pembrolizumab + gemcitabine + albumin-bound paclitaxel).